Axsome Therapeutics, Inc. (AXSM)
About Axsome Therapeutics, Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $638.5M
- Net income
- -$183.2M
- Total assets
- $689.8M
- Market cap
- $12.0B
- Operating margin
- -26.1%
- Net margin
- -28.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $638.5M
- Operating expenses
- $805.3M
- Operating income
- -$166.8M
- Income tax
- -$530.0K
- Net income
- -$183.2M
- EPS (basic)
- $-3.68
- EPS (diluted)
- $-3.68
Balance sheet
- Total assets
- $689.8M
- Current assets
- $589.0M
- Total liabilities
- $601.5M
- Current liabilities
- $378.8M
- Shareholders’ equity
- $88.3M
Cash flow
- Operating cash flow
- -$93.4M
- Investing cash flow
- -$480.0K
- Financing cash flow
- $101.5M
- Net cash flow
- $7.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $12.0B
- EPS (diluted)
- $-3.68
- Shares outstanding
- 49.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 19, 2015
Axsome Therapeutics, Inc. (AXSM) Stock Price
- Reported a net loss of $183.2M in FY2025.
- Trading 6% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Axsome Therapeutics, Inc..
Write a review
News about Axsome Therapeutics, Inc.
News & sentiment via Polygon.io
Axsome Therapeutics, Inc.: frequently asked questions
Is Axsome Therapeutics, Inc. an American company?
Yes — Axsome Therapeutics, Inc. is an American company headquartered in New York, New York. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Axsome Therapeutics, Inc. headquartered?
Axsome Therapeutics, Inc. is headquartered in New York, New York, United States.
Is Axsome Therapeutics, Inc. publicly traded?
Yes — Axsome Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol AXSM on the NASDAQ.
What does Axsome Therapeutics, Inc. do?
Axsome Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Axsome Therapeutics, Inc. founded?
Axsome Therapeutics, Inc. was founded in 2012.
